Company Overview
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Why Investors Should Care
Generates a return on equity of 144.3%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $102.48M (+65.2% YoY); net profit $-191.09M.
- Trailing 12 Months Year-on-year growth — revenue -84.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.98% |
| 1 Year: | -84.60% |
Stock Price Performance
| 1 Year: | +148.05% |
| 6 Months: | -23.54% |
| 3 Months: | -24.83% |
| 1 Month: | -24.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 144.3%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 53.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STRO Sutro Biopharma, Inc. PHARMA | 19.10 | -1.10 | $316.70M | 0.00% | -106.34% | 144.27% | 6.98% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 5.79M | 5.70M | 7.84M | - | 8.63M | 10.53M | 12.28M | 11.30M | 7.15M | 9.47M | 17.82M | 8.28M | 14.66M | 28.05M | 8.52M | 5.90M | 28.10M | 25.15M | 12.67M | 10.41M | 16.92M | 13.01M | 25.71M | 8.52M | 17.40M | 63.74M | 9.69M | 11.65M | 14.52M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.87M | 48.67M | 48.59M | 45.30M | 44.14M |
| Operating Income | - | - | -1.06M | - | -11.70M | -12.09M | -10.16M | - | -14.27M | -13.69M | -12.73M | - | -19.18M | -16.42M | -10.62M | - | -19.01M | -9.80M | -34.67M | -39.13M | -19.38M | -21.21M | -42.24M | -46.18M | -44.01M | -56.59M | -48.69M | -67.92M | -47.47M | 15.08M | -38.90M | -33.66M | -29.61M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -63.42M | 1.07M | -44.55M | -34.89M | -26.74M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.64M | 10.69M | 10.41M | 10.33M | 10.48M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -75.96M | -11.52M | -56.86M | -46.84M | -38.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00K | -18.00K | 0 | -82.00K | -15.00K |
| Net Income | -1.11M | -1.81M | -1.42M | -15.34M | -12.05M | -11.54M | -10.24M | -1.49M | -14.25M | -13.79M | -12.91M | -14.79M | -19.59M | 29.87M | 17.14M | -59.54M | -30.36M | -6.15M | -30.90M | -39.11M | -26.01M | -19.49M | -50.05M | -38.52M | -49.28M | -58.21M | -48.02M | -48.79M | -75.97M | -11.50M | -56.86M | -46.76M | -38.48M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.60 | -0.56 | - | -0.84 | 0.94 | 0.45 | -1.48 | - | -0.13 | -0.67 | -0.84 | -0.55 | -0.37 | -0.85 | -0.64 | -0.81 | -0.59 | -0.59 | -0.59 | -9.08 | -1.40 | -6.70 | - | -2.94 |
| R&D Expense | - | - | 13.67M | - | 13.08M | 13.75M | 12.64M | - | 15.18M | 16.14M | 16.90M | - | 17.62M | 17.24M | 19.36M | - | 22.56M | 25.31M | 26.60M | 29.99M | 32.33M | 31.71M | 39.40M | 41.59M | 45.67M | 56.88M | 62.02M | 62.11M | 51.60M | 38.33M | 39.85M | - | 36.55M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.73M | 51.74M | 38.42M | 42.74M | 42.72M | - | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 196.72M | 243.01M | 300.50M | 207.44M |
| Operating Income | 1.36M | -19.27M | -37.22M | -55.47M | -71.06M | - | -128.94M | -89.28M | -238.45M | -104.95M |
| EBITDA | - | - | - | - | - | - | -107.67M | -58.03M | -186.81M | -141.79M |
| Interest Expense | - | - | - | - | - | - | 3.35M | 23.75M | 31.07M | 42.06M |
| Pretax Income | - | - | - | - | - | - | -116.70M | -88.60M | -225.10M | -191.18M |
| Tax Provision | - | - | - | - | - | - | 2.50M | 18.19M | 2.36M | -93.00K |
| Net Income | 1.70M | -19.69M | -35.32M | -119.20M | -32.13M | - | -119.20M | -106.79M | -227.46M | -191.09M |
| Diluted EPS | - | - | - | - | -0.99 | - | -23.50 | -17.80 | -29.40 | -22.49 |
| R&D Expense | 43.55M | 54.64M | 54.26M | 65.61M | 76.96M | 104.40M | 137.17M | 180.43M | 252.04M | 166.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 40.77M | 223.14M | 156.37M | 394.11M | - | 406.94M | 470.74M | 387.21M | 173.83M |
| Current Assets | - | - | - | - | - | - | - | 353.15M | 421.54M | 343.31M | 150.93M |
| Cash & Equivalents | - | 11.59M | 22.02M | 125.30M | 4.96M | 206.15M | - | 47.25M | 69.27M | 190.30M | 58.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | 7.12M | 36.08M | 8.62M | 3.98M |
| Total Liabilities | - | - | 47.27M | 91.60M | 58.58M | 62.06M | - | 189.90M | 321.09M | 342.61M | 306.28M |
| Current Liabilities | - | - | 31.96M | 36.42M | 32.97M | 29.60M | - | 66.55M | 93.75M | 131.89M | 75.13M |
| Long Term Debt | - | - | - | 10.00M | 8.88M | 24.55M | 15.74M | 3.77M | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 50.43M | 33.63M | 23.15M | 15.67M |
| Total Equity | -93.90M | -90.90M | -109.00M | 131.54M | 97.79M | 332.05M | - | 217.05M | 149.65M | 44.60M | -132.45M |
| Shares Outstanding | - | - | - | - | - | - | - | 5.75M | 6.10M | 8.25M | 8.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.15M | -37.07M | 12.68M | -65.02M | -67.80M | - | 3.55M | -111.62M | -191.54M | -177.23M |
| Investing Cash Flow | 9.59M | 32.60M | -80.19M | -51.13M | 604.00K | - | -35.02M | -3.92M | 218.51M | 45.01M |
| Financing Cash Flow | 177.00K | 14.64M | 170.78M | -4.18M | 269.25M | - | 48.31M | 137.55M | 94.05M | 44.00K |
| Capital Expenditure | -4.39M | -3.32M | -1.56M | - | - | - | -7.86M | -4.32M | -3.10M | -1.70M |
| Free Cash Flow | -17.55M | -40.39M | 11.13M | - | - | - | -4.31M | -115.93M | -194.64M | -178.93M |
| Net Change in Cash | - | - | - | - | - | - | 16.84M | 22.01M | 121.02M | -132.17M |
| Share Buybacks | - | - | - | - | - | 7.00K | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 2.3% | -37.2% | -96.9% | -129.8% | -166.3% | - | -190.3% | -58.1% | -384.3% | -102.4% |
| Net Margin % | 2.8% | -38.1% | -91.9% | -278.9% | -75.2% | - | -175.9% | -69.5% | -366.6% | -186.5% |
| ROE % | -1.9% | 18.1% | -26.8% | -121.9% | -9.7% | - | -54.9% | -71.4% | -510.0% | 144.3% |
| ROCE % | - | -218.7% | -19.9% | -44.9% | -19.5% | - | -37.9% | -23.7% | -93.4% | -106.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Perceptive Advisors Llc | 7.87% | 1.30M | $20.02M |
| 2 | BVF Inc. | 7.55% | 1.25M | $19.20M |
| 3 | Affinity Asset Advisors, Llc | 7.07% | 1.17M | $17.99M |
| 4 | Blackrock Inc. | 6.77% | 1.12M | $17.22M |
| 5 | Samsara BioCapital, LLC | 6.41% | 1.06M | $16.30M |
| 6 | Kynam Capital Management, LP | 5.26% | 872.56K | $13.39M |
| 7 | Orbimed Advisors LLC. | 4.49% | 743.94K | $11.41M |
| 8 | Balyasny Asset Management LP | 4.29% | 711.16K | $10.91M |
| 9 | Vanguard Capital Management LLC | 4.19% | 694.22K | $10.65M |
| 10 | Eventide Asset Management LLC | 3.53% | 585.26K | $8.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STRO
Sutro Biopharma Stock Price Forecast. Should You Buy STRO? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1zTkk3R0lyOGJ5U2UzZElCVVBEWHVFRDJjM2tJRXRLVDRoWjFIcE5zOFA0NnFaT3UyaG5WNm95NDFsd1VpRFBOdQ?oc=5" target="_blank">Sutro Biopharma Stock Price Forecast. Should You Buy STRO?</a> &…
STRO Stock Plummets 15% — What Drove The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQQW0wbV83RW9FcXNaeVA3S0FUTTNGV0Fid0JaR0FidnFlOGEyd1g1V2FQRlBuWXM2X2owcERPNFZBOVdyQW9ZVlE0eTVZTGJDNFhtSzhWMzRyQlZMSXpTVUNyQ0lFRnZLejBqVjYySGYzSnlFSHkybVdLS2FrWjYzMUxtTUFGMV96SEFodT…
(STRO) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxORlkxS3BVaWU1eGc0YTlQRWtMYXJpNktzaWZJMERGUm9vS1FabV93NElwakhGWDhKSjJWWmYydk9FRzJTS2VtdWFVc19YN2wxVW1HeV9TZTFWT0ZoT19Ld2JKTTN0ZXJZSjdwYjdXSUZDUEtkd2ZmN1ozZ3c5RXM2d2tlZ1N5MnpZRlEtSF…
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQLWo4b1h5cmNJejIyT19WRTNndk1kTDVLYm9DSXd5N1YzWHJmM0lxX0pmRC1CcnBJS2NBRUhRZjg4dktyX3pzdHQ2TjFfMDN2NnpkMEdFd2lJemJOQVZhXzhVdDZaZ0VNV2lfYVh2LUhNSXMwS2UwSGRjQXVURS1JOVlXSEQzWVFaaERocG…
Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQeWVfZWhVS1d4cWZabmN0QmJIX2tGZjNqckxoOG1SNjhuLU16STA2N1J1WFUtc3VoczdrNkFyUkZVZzZFT1N2dVl5eEIxSFNIczd3b05lOUtnSExMUW02SjNrbktuTWgzaGo2UHVmZW1uSHJpbHJyMjRtZkpLcTh4d21BSjVVVnNYTnY1Nk…
Cancer-drug maker Sutro projects cash runway into 2028 as ADC pipeline advances - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOa0R0cEk5Q3Y0X0VBWFp3c2MwbE9nOXNZTWZnLUVDYV9JMy1OSkxkNkIwaENsR1NoYllwdU91U3BrNGNGLURuTHJmYkVPX0ZyaUxLNHpjZWREcVNHQlVxazNoMWtLNHVoMVZ5U1JlSVg5UHNyeWFmVXc3RzFWeS02bzlzRy0tbUVYTEkxRF…
STRO — Frequently Asked Questions
What is the current share price of Sutro Biopharma, Inc. (STRO)?
As of 2026-09-19 21:16 PDT, Sutro Biopharma, Inc. (STRO) trades at $19.10 on NasdaqGM. Its 52-week range is $7.30 to $40.91.
What is the market capitalisation of STRO?
Sutro Biopharma, Inc. (STRO) has a market capitalisation of $316.70M on NasdaqGM.
What is the P/E ratio of STRO?
STRO trades at a trailing price-to-earnings (P/E) ratio of -1.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -2.46.
What is the return on equity (ROE) of STRO?
STRO has a return on equity (ROE) of 144.27%. Its return on capital employed (ROCE) is -106.34%.
Is STRO a good stock to buy?
This page provides a data-driven analysis of Sutro Biopharma, Inc. (STRO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.